Anti-D immunoglobulin in RhD prophylaxis

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 105, Issue 2, 1998, Pages 129-134

  Robson, Stephen C ^a   Lee, Douglas ^b   Urbaniak, Stan ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Lancaster Blood Centre   (United Kingdom)

^c SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY;

ALLOIMMUNIZATION; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; HUMAN; IMMINENT ABORTION; NOTE; PRIORITY JOURNAL; RHESUS INCOMPATIBILITY; SPONTANEOUS ABORTION; VAGINA BLEEDING;

ABORTION, THREATENED; CONSENSUS DEVELOPMENT CONFERENCES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MATERNAL MORTALITY; POSTNATAL CARE; PRACTICE GUIDELINES; PREGNANCY; PRENATAL CARE; PUERPERAL DISORDERS; RANDOMIZED CONTROLLED TRIALS; RH ISOIMMUNIZATION; RHO(D) IMMUNE GLOBULIN; UTERINE HEMORRHAGE;

EID: 0031883093     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1998.tb10039.x     Document Type: Note

References (30)

1. Standing Medical Advisory Committee. Haemolytic Disease of the Newborn. London: Department of Health and Social Security, 1976.
2. Standing Medical Advisory Committee. Memorandum on haemolytic disease of the newborn, 1976—addendum 1981. London: Department of Health and Social Security, 1982.
3. National Blood Transfusion Service Immunoglobulin Working Party. Recommendations for the use of anti-D immunoglobulin. Prescribers ‘ Journal 1991; 31: 137–145.
4. Mollison PL, Engelhet CP, Contreras M. Haemolytic disease of the fetus and newborn. In: Blood Transfusion in Clinical Medicine. Oxford: Blackwell Science 1997; 543–591.
5. Murphy KW, Whitfield CR. Rhesus disease in this decade. Contemp Rev Obstet Gynaecol 1994; 6: 61–67.
6. Hughes RG, Craig JI, Murphy WG, Greer IA. Causes and clinical consequences of Rhesus (D) haemolytic disease of the newborn: a study of a Scottish population, 1985–1990. Br J Obstet Gynaecol 1994; 101: 297–300.
7. Howard HL, Martlew VJ, McFadyen IR, Clarke CA. A study of the incidence of, and reasons for, RhD isoimmunisation in RhD-negative pregnant women [abstract]. Presentation at the Joint Royal College of Physicians of Edinburgh and the Royal College of Obstetricians and Gynaecologists Consensus Conference on Anti-D Prophylaxis; Edinburgh; 8–9 Apr 1997. Br J Obstet Gynaecol 1998; 105 Suppl 17. In press.
8. Howard HL, Martlew VJ, McFadyen IR, Clarke CA. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed Br J Obstet Gynaecol 1997; 104: 37–41.
9. Lee D, Rawlinson VI. Multicentre trial of antepartum low-dose anti D immunoglobulin. Trans J Med 1995; 5: 15–19.
10. Ghosh S, Murphy WG. Implementation of the rhesus prevention programme: a prospective study. Scot Med J 1994; 39: 147–149.
11. Vinall P, Kirkham J, McSweeney E, Flanagan P. An audit of anti-D sensitisation in Yorkshire [abstract]. Presentation at the Joint Royal College of Physicians of Edinburgh and the Royal College of Obstetricians and Gynaecologists Consensus Conference on Anti-D Prophylaxis; Edinburgh; 8–9 Apr 1997. Br J Obstet Gynaecol 1998; 105 Suppl 17. In press.
12. Proceedings of the Joint Royal College of Physicians of Edinburgh and the Royal College of Obstetricians and Gynaecologists Consensus Conference on Anti-D Prophylaxis; Edinburgh; 8–9 Apr 1997. Br J Obstet Gynaecol 1998; 105 Suppl 17. In press.
13. Bowman JM. The prevention of Rh immunisation. Trans J Med Rev 1988; 2: 129–150.
14. Zipurski A, Israels LG. The pathogenesis and prevention of Rh irmnunisation. Can Med Assoc J 1967; 91: 1254–1257.
15. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study of general practice. BMJ 1997; 315: 32–34.
16. Office for National Statistics. Population Trends, Vol 86. London: ONS, 1996 1 5
17. Davey MG, Zipurski A. McMaster Conference on prevention of Rh immunisation, September 1977. Vox Sang 1979; 36: 50–64.
18. Bowman JM, Chown B, Lewis M, Pollock JM. Rh isoimmunisaton during pregnancy: antenatal prophylaxis. Can MedAssoc J 1978; 118: 623–627.
19. Tovey LAD, Townley A, Stevenson B, Taverner J. The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. Lancet 1983; 2: 244–246.
20. Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental haemorrhage during pregnancy and after delivery. Vox Sang 1986; 51: 117–121.
21. Hutchet J, Dallcmange S, Huchet C, Brossard Y, Larsen M, Parnet-Mathieu F. Application ante-partum du traitement preventif d’immunisation Rhésus D chez les femmes Rhésus négatif. Evaluation paralléle des passages transplacentaires d’hématies foetales. Resultats d’une étude multicentrique menée en région parisienne. J Gynecol Obstet Biol Reprod 1987; 16: 101–111.
22. Grant JM. Antenatal prophylaxis—opposing [abstract]. Presentation at the Joint Royal College of Physicians of Edinburgh and the Royal 32–34. College of Obstetricians and Gynaecologists Consensus Conference on Anti-D Prophylaxis; Edinburgh; 8–9 Apr 1997. Br J Obstet Gynaecol 1998; 105 Suppl 17. Inpress.
23. Bowman JM, Pollack JM. Antenatal prophylaxis of Rh isoimmunisation: 28-weeks gestation service programme. Can Med Assoc J 1978; 118: 627–630.
24. Bowman JM. Antenatal prophylaxis-overview [abstract]. Presentation at the Joint Royal College of Physicians of Edinburgh and the Royal College of Obstetricians and Gynaecologists Consensus Conference on Anti-D Prophylaxis; Edinburgh; 8–9 Apr 1997. Br J Obstet Gynaecol 1998; 105 Suppl 17. In press.
25. Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transf Med Rev 1987; 1: 101–112.
26. Cairns JA. Economics of antenatal prophylaxis. Presentation at the Joint Royal College of Physicians of Edinburgh and the Royal College of Obstetricians and Gynaecologists Consensus Conference on Anti-D Prophylaxis; Edinburgh; 8–9 Apr. 1997. Br J Obstet Gynaecol 1998; 105 Suppl 17. In press.
27. Vick S, Cairns J, Urbaniak S, Whitfield C, Alaeddin R. Cost-effectiveness of antenatal anti-D prophylaxis. Health Economics 1996; 5: 319–328.
28. Torrance GW, Zipursky A. Cost-effectiveness of anteparturn prevention of Rh immunisation. Clin Perinatol 1984; 11: 267–281.
29. De Silva M. The procurement of hyperimmune anti-D plasma for anti D Ig manufacture in England [abstract]. Presentation at the Joint Royal College of Physicians of Edinburgh and the Royal College of Obstetricians and Gynaecologists Consensus Conference on Anti-D Prophylaxis; Edinburgh; 8–9 Apr. 1997. Br J Obstet Gynaecol 1998; 105 Suppl 17. In press.
30. De Crespigny L, Davison G. Anti-D administration in early pregnancy—time for a new protocol. Aust NZ J Obstet Gynaecol 1995; 35: 385–387.